Ono, Takaaki http://orcid.org/0000-0003-3922-7432
Hino, Masayuki
Matsumura, Itaru
Fujisawa, Shin
Ishizawa, Kenichi
Sakaida, Emiko
Sekiguchi, Naohiro
Ono, Chiho
Aizawa, Mana
Tanetsugu, Yusuke
Koide, Yuichiro
Takahashi, Naoto
Clinical trials referenced in this document:
Documents that mention this clinical trial
Bosutinib in Japanese patients with newly diagnosed chronic-phase chronic myeloid leukemia: final 3-year follow-up results of a phase 2 study
https://doi.org/10.1007/s12185-022-03435-4
Safety profile of bosutinib in Japanese versus non-Japanese patients with chronic myeloid leukemia: a pooled analysis
https://doi.org/10.1007/s12185-022-03314-y
Funding for this research was provided by:
Pfizer
Article History
Received: 17 March 2022
Revised: 29 July 2022
Accepted: 31 July 2022
First Online: 13 August 2022
Declarations
:
: Takaaki Ono reports honoraria from Bristol Myers Squibb, Celgene, Merck Sharp & Dohme, Ono, Otsuka, Novartis, Pfizer, and Takeda; and research funding from Celgene, Chugai, Kyowa Hakko Kirin, Merck Sharp & Dohme, and Ono. Masayuki Hino reports research funding from Novartis, Otsuka, and Pfizer; and honoraria from Bristol Myers Squibb, Novartis, Otsuka, and Pfizer. Itaru Matsumura reports research funding from Otsuka and Pfizer; speakers bureau with Bristol Myers Squibb and Novartis; and consultancy with Otsuka. Shin Fujisawa reports honoraria and research funding from Bristol Myers Squibb, Novartis, Otsuka, and Pfizer. Kenichi Ishizawa reports research funding from Otsuka and Pfizer; and speakers bureau with Bristol Myers Squibb and Novartis. Emiko Sakaida reports research funding from Bristol Myers Squibb, Chugai, Kyowa Kirin, and Ono; and honoraria from Bristol Myers Squibb, Novartis, and Pfizer. Naohiro Sekiguchi reports research funding from A2 Healthcare, Astellas, Bristol Myers Squibb, Daiichi Sankyo, Janssen, Merck Sharp & Dohme, Ono, Otsuka, Pfizer, PPD-SNBL, and Sumitomo Dainippon Pharma. Chiho Ono reports employment by Pfizer Japan Inc and stock options for Pfizer. Mana Aizawa, Yusuke Tanetsugu, and Yuichiro Koide report employment for Pfizer R&D Japan G.K. Naoto Takahashi reports research funding and honoraria from Novartis, Otsuka, and Pfizer; and research funding from Asahi Kasei, Chugai, Eisai, Kyowa Hakko Kirin, Ono, and Toyama Kagaku.